New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - danazol 200mg;   - capsule - 200 mg - active: danazol 200mg   excipient: gelatin lactose monohydrate magnesium stearate maize starch purified talc sulfur dioxide titanium dioxide

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - danazol 100mg;   - capsule - 100 mg - active: danazol 100mg   excipient: gelatin lactose monohydrate magnesium stearate maize starch purified talc

United States - English - NLM (National Library of Medicine)

lannett company, inc. - danazol (unii: n29qww3buo) (danazol - unii:n29qww3buo) - danazol 50 mg - endometriosis. danazol capsules are indicated for the treatment of endometriosis amenable to hormonal management. hereditary angioedema. danazol capsules are indicated for the prevention of attacks of angioedema of all types (cutaneous, abdominal, laryngeal) in males and females. danazol capsules should not be administered to patients with: - undiagnosed abnormal genital bleeding. - markedly impaired hepatic, renal, or cardiac function. - pregnancy (see warnings ). - breast feeding. - porphyria-danazol capsules can induce ala synthetase activity and hence porphyrin metabolism. - androgen-dependent tumor. - active thrombosis or thromboembolic disease and history of such events. - hypersensitivity to danazol.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - danazol -

United States - English - NLM (National Library of Medicine)

proficient rx lp - danazol (unii: n29qww3buo) (danazol - unii:n29qww3buo) - endometriosis. danazol capsules are indicated for the treatment of endometriosis amenable to hormonal management. hereditary angioedema. danazol capsules are indicated for the prevention of attacks of angioedema of all types (cutaneous, abdominal, laryngeal) in males and females. danazol capsules should not be administered to patients with:

United States - English - NLM (National Library of Medicine)

chartwell rx, llc. - danazol (unii: n29qww3buo) (danazol - unii:n29qww3buo) - endometriosis. danazol capsules are indicated for the treatment of endometriosis amenable to hormonal management. hereditary angioedema. danazol capsules are indicated for the prevention of attacks of angioedema of all types (cutaneous, abdominal, laryngeal) in males and females. danazol capsules should not be administered to patients with: - undiagnosed abnormal genital bleeding. - markedly impaired hepatic, renal, or cardiac function. - pregnancy (see warnings). - breast feeding. - porphyria-danazol capsules can induce ala synthetase activity and hence porphyrin metabolism. - androgen-dependent tumor. - active thrombosis or thromboembolic disease and history of such events. - hypersensitivity to danazol.

Australia - English - Department of Health (Therapeutic Goods Administration)

catalent australia pty ltd - garlic oil -

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - metformin hydrochloride, quantity: 500 mg; glibenclamide, quantity: 5 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; povidone; magnesium stearate; microcrystalline cellulose; titanium dioxide; lactose monohydrate; hypromellose; quinoline yellow; iron oxide yellow; macrogol 4000; iron oxide red - second line treatment of diabetes mellitus type ii in adult patients whose glycaemic control is inadequate after diet and exercise alone and where combined therapy with metformin and glibenclamide is appropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - metformin hydrochloride, quantity: 500 mg; glibenclamide, quantity: 2.5 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; povidone; magnesium stearate; microcrystalline cellulose; titanium dioxide; lactose monohydrate; hypromellose; iron oxide yellow; macrogol 4000; iron oxide red; iron oxide black - second line treatment of diabetes mellitus type ii in adult patients whose glycaemic control is inadequate after diet and exercise alone and where combined therapy with metformin and glibenclamide is appropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - metformin hydrochloride, quantity: 250 mg; glibenclamide, quantity: 1.25 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; povidone; magnesium stearate; microcrystalline cellulose; titanium dioxide; lactose monohydrate; hypromellose; iron oxide yellow; purified talc; macrogol 4000 - second line treatment of diabetes mellitus type ii in adult patients whose glycaemic control is inadequate after diet and exercise alone and where combined therapy with metformin and glibenclamide is appropriate.